Home>>Peptides>>Secretin (28-54), human TFA

Secretin (28-54), human TFA (Synonyms: Human secretin TFA)

Catalog No.GC38946

Secretin (28-54), human TFA is a 27-amino acid residue C-terminally amidated peptide, which acts on human secretin receptors.

Products are for research use only. Not for human use. We do not sell to patients.

Secretin (28-54), human TFA Chemical Structure

Size Price Stock Qty
1mg
$167.00
In stock
5mg
$501.00
In stock
10mg Please Inquire Please Inquire
50mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Secretin (28-54), human TFA is a 27-amino acid residue C-terminally amidated peptide, which acts on human secretin receptors[1].

Secretin is a hormone produced and secreted from the endocrine S cells in response to the gastric acid and lipid components. Secretin potentiates enzyme secretion from the acinar cell. Secretin is also a putative mitogen to promote pancreatic growth. In the stomach and gall bladder, Secretin inhibits gastric emptying and acid release and stimulates biliary output of water and bicarbonate. Secretin elicits its biological effects by interacting with specific cell surface receptors[1].

[1]. Pang RT, et al. Role of N-linked glycosylation on the function and expression of the human secretin receptor. Endocrinology. 1999 Nov;140(11):5102-11.

Reviews

Review for Secretin (28-54), human TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Secretin (28-54), human TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.